Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study.
Journal
Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
22
02
2022
accepted:
08
06
2022
revised:
18
05
2022
pubmed:
19
6
2022
medline:
9
9
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
The short and long-term outcomes of children with anti-Ro/La-related congenital heart block treated with a combined maternal-neonatal therapy protocol were compared with those of controls treated with other therapies. Sixteen mothers were treated during pregnancy with a therapy consisting of daily oral fluorinated steroids, weekly plasma exchange and fortnightly intravenous immunoglobulins and their neonates with intravenous immunoglobulins (study group); 19 mothers were treated with fluorinated steroids alone or associated to intravenous immunoglobulins or plasma exchange (control group). The combined-therapy children showed a significantly lower progression rate from 2nd to 3rd degree block at birth, a significant increase in heart rate at birth and a significantly lower number of pacemaker implants during post-natal follow-up with respect to those treated with the other therapies. The combined therapy produced better short and long term outcomes with respect to the other therapies studied.
Identifiants
pubmed: 35717457
doi: 10.1038/s41372-022-01431-4
pii: 10.1038/s41372-022-01431-4
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Steroids, Fluorinated
0
Betamethasone
9842X06Q6M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1161-1168Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Skog A, Lagnefeldt L, Conner P, Wahren-Herlenius M, Sonesson SE. Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block. Acta Obstet Gynecol Scand. 2016;95:98–105.
pubmed: 26411741
doi: 10.1111/aogs.12785
Ambrosi A, Wahren-Herlenius M. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Res Ther. 2012;14:208.
pubmed: 22546326
pmcid: 3446439
doi: 10.1186/ar3787
Trucco SM, Jaeggi E, Cuneo B, Moon-Grady AJ, Silverman E, Silverman N, et al. Use of intravenous gamma globulin and corticosteroids in the treatment of maternal autoantibody-mediated cardiomyopathy. J Am Coll Cardiol. 2011;57:715–23.
pubmed: 21292131
doi: 10.1016/j.jacc.2010.09.044
Morel N, Lévesque K, Maltret A, Baron G, Hamidou M, Orquevaux P, et al. “Lupus néonatal” group. Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupus. Int J Cardiol. 2017;248:263–9.
pubmed: 28843719
doi: 10.1016/j.ijcard.2017.07.100
Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol. 2015;11:301–12.
pubmed: 25800217
pmcid: 5551504
doi: 10.1038/nrrheum.2015.29
Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum. 2004;50:1253–61.
pubmed: 15077309
doi: 10.1002/art.20126
Eliasson H, Sonesson SE, Sharland G, Granath F, Simpson JM, Carvalho JS, et al. Fetal Working Group of the European Association of Pediatric Cardiology. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation. 2011;124:1919–26.
pubmed: 21986286
doi: 10.1161/CIRCULATIONAHA.111.041970
Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009;103:1102–6.
pubmed: 19361597
pmcid: 2730772
doi: 10.1016/j.amjcard.2008.12.027
Mofors J, Eliasson H, Ambrosi A, Salomonsson S, Skog A, Fored M, et al. Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero. Ann Rheum Dis. 2019;78:696–703.
pubmed: 30808622
doi: 10.1136/annrheumdis-2018-214406
Kuleva M, Le Bidois J, Decaudin A, Villain E, Costedoat-Chalumeau N, Lemercier D, et al. Clinical course and outcome of antenatally detected atrioventricular block: experience of a single tertiary centre and review of the literature. Prenat Diagn. 2015;35:354–61.
pubmed: 25487821
doi: 10.1002/pd.4547
Mofors J, Sonesson SE, Wahren-Herlenius M. Effects of maternal medication on long-term outcome in congenital heart block remain to be established. Response to: ‘Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero’ by Satis et al. Ann Rheum Dis. 2020;79:e95.
pubmed: 31272943
doi: 10.1136/annrheumdis-2019-215677
Cuneo BF, Sonesson SE, Levasseur S, Moon-Grady AJ, Krishnan A, Donofrio MT, et al. Home monitoring for fetal heart rhythm during Anti-Ro Pregnancies. J Am Coll Cardiol. 2018;72:1940–51.
pubmed: 30309472
doi: 10.1016/j.jacc.2018.07.076
Michael A, Radwan AA, Ali AK, Abd-Elkariem AY, Shazly SA. Middle-East Obstetrics and Gynecology Graduate Education (MOGGE) Foundation Research Group. Use of antenatal fluorinated corticosteroids in management of congenital heart block: Systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol X. 2019;4:100072.
pubmed: 31517303
pmcid: 6728741
doi: 10.1016/j.eurox.2019.100072
Hoxha A, Mattia E, Zanetti A, Carrara G, Morel N, Costedoat-Chalumeau N, et al. Fluorinated steroids are not superior to any treatment to ameliorate the outcome of autoimmune mediated congenital heart block: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2020;38:783–91.
pubmed: 32573408
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020;76:292–302.
pubmed: 32674792
pmcid: 7394202
doi: 10.1016/j.jacc.2020.05.045
Ruffatti A, Milanesi O, Chiandetti L, Cerutti A, Gervasi MT, De Silvestro G, et al. A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block? Lupus. 2012;21:666–71.
pubmed: 22187163
doi: 10.1177/0961203311430969
Di Mauro A, Caroli Casavola V, Favia Guarnieri G, Calderoni G, Cicinelli E, Laforgia N. Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block. BMC Pregnancy Childbirth. 2013;13:220.
pubmed: 24286473
pmcid: 4219454
doi: 10.1186/1471-2393-13-220
Ruffatti A, Marson P, Svaluto-Moreolo G, Marozio L, Tibaldi M, Favaro M, et al. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmun Rev. 2013;12:768–73.
pubmed: 23340276
doi: 10.1016/j.autrev.2013.01.002
Martínez-Sánchez N, Robles-Marhuenda Á, Álvarez-Doforno R, Viejo A, Antolín-Alvarado E, Deirós-Bronte L, et al. The effect of a triple therapy on maternal anti-Ro/SS-A levels associated to fetal cardiac manifestations. Autoimmun Rev. 2015;14:423–8.
pubmed: 25599954
doi: 10.1016/j.autrev.2015.01.005
Ruffatti A, Favaro M, Brucato A, Ramoni V, Facchinetti M, Tonello M, et al. Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block. Transfus Apher Sci. 2015;53:269–78.
pubmed: 26626966
doi: 10.1016/j.transci.2015.11.006
Ruffatti A, Cerutti A, Favaro M, Del Ross T, Calligaro A, Hoxha A, et al. Plasmapheresis, intravenous immunoglobulins and bethametasone - a combined protocol to treat autoimmune congenital heart block: a prospective cohort study. Clin Exp Rheumatol. 2016;34:706–13.
pubmed: 27385463
Brito-Zerón P, Pasoto SG, Robles-Marhuenda A, Mandl T, Vissink A, Armagan B.Sjögren Big Data Consortium et al. Autoimmune congenital heart block and primary Sjögren’s syndrome: characterisation and outcomes of 49 cases. Clin Exp Rheumatol. 2020;38:95–102.
pubmed: 33025893
Kertesz NJ, Fenrich AL, Friedman RA. Congenital complete atrioventricular block. Tex Heart Inst J. 1997;24:301–7.
pubmed: 9456483
pmcid: 325472
Friedman D, Duncanson LJ, Glickstein J, Buyon J. A review of congenital heart block. Images Paediatr Cardiol. 2003;5:36–48.
pubmed: 22368629
pmcid: 3232542
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61:e6–75.
pubmed: 23265327
doi: 10.1016/j.jacc.2012.12.014
Tonello M, Ruffatti A, Marson P, Tison T, Marozio L, Hoxha A, et al. Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. Transfusion. 2015;55:1782–6.
pubmed: 25825254
doi: 10.1111/trf.13046
van der Lugt NM, van Kampen A, Walther FJ, Brand A, Lopriore E. Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. Vox Sang. 2013;105:236–43.
pubmed: 23782272
doi: 10.1111/vox.12036
Klauninger R, Skog A, Horvath L, Winqvist O, Edner A, Bremme K, et al. Serologic follow-up of children born to mothers with Ro/SSA autoantibodies. Lupus. 2009;18:792–8.
pubmed: 19578103
doi: 10.1177/0961203309103188
Lebwohl B, Rubio-Tapia A. Epidemiology, presentation, and diagnosis of celiac disease. Gastroenterology. 2021;160:63–75.
pubmed: 32950520
doi: 10.1053/j.gastro.2020.06.098
Bishop TW. Mental disorders and learning disabilities in children and adolescents: learning disabilities. FP Ess. 2018;475:18–22.
Kelly EN, Sananes R, Chiu-Man C, Silverman ED, Jaeggi E. Prenatal anti-Ro antibody exposure, congenital complete atrioventricular heart block, and high-dose steroid therapy: impact on neurocognitive outcome in school-age children. Arthritis Rheumatol. 2014;66:2290–6.
pubmed: 24756962
doi: 10.1002/art.38675
Fredi M, Andreoli L, Bacco B, Bertero T, Bortoluzzi A, Breda S, et al. First report of the Italian registry on immune-mediated congenital heart block (Lu.Ne Registry). Front Cardiovasc Med. 2019;6:11.
pubmed: 30873413
pmcid: 6404544
doi: 10.3389/fcvm.2019.00011
Routsias JG, Kyriakidis NC, Friedman DM, Llanos C, Clancy R, Moutsopoulos HM, et al. Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum. 2011;63:2783–9.
pubmed: 21618202
pmcid: 3551293
doi: 10.1002/art.30464
Arroyave CM, Puente Ledezma F, Montiel Amoroso G, Martínez García AC. Myocardiopathy diagnosed in utero in a mother with SS-A antibodies treated with plasmapheresis. Ginecol Obstet Mex. 1995;63:134–7.
pubmed: 7744295
David AL, Ataullah I, Yates R, Sullivan I, Charles P, Williams D. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol. 2010;116:543–7.
pubmed: 20664449
doi: 10.1097/AOG.0b013e3181e75a4a
Angelini A, Moreolo GS, Ruffatti A, Milanesi O, Thiene G. Images in cardiovascular medicine. Calcification of the atrioventricular node in a fetus affected by congenital complete heart block. Circulation. 2002;105:1254–5.
pubmed: 11889022
doi: 10.1161/hc1002.103433
Cuneo BF, Ambrose SE, Tworetzky W. Detection and successful treatment of emergent anti-SSA-mediated fetal atrioventricular block. Am J Obstet Gynecol. 2016;215:527–8.
pubmed: 27418449
doi: 10.1016/j.ajog.2016.07.002
Brucato A, Ramoni V, Gerosa M, Pisoni MP. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol. 2011;117:177.
pubmed: 21173668
doi: 10.1097/AOG.0b013e3182042972
Ruffatti A, Favaro M, Cozzi F, Tonello M, Grava C, Lazzarin P, et al. Anti-SSA/Ro-related congenital heart block in two family members of different generations: Comment on the article by Clancy et al. Arthritis Rheum. 2005;52:1623–5.
pubmed: 15880834
doi: 10.1002/art.21152
Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus. 2002;11:145–51.
pubmed: 11999879
doi: 10.1191/0961203302lu173oa
Bosch T. Therapeutic apheresis—state of the art in the year 2005. Ther Apher Dial. 2005;9:459–68.
pubmed: 16354277
doi: 10.1111/j.1744-9987.2005.00306.x
Colpo A, Marson P, Pavanello F, Tison T, Gervasi MT, Zambon A, et al. Therapeutic apheresis during pregnancy: a single center experience. Transfus Apher Sci. 2019;58:652–8.
pubmed: 31522920
doi: 10.1016/j.transci.2019.07.009